Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MONA LISA ALATTAR

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1558624239
CMS profile
1119534
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,911.03

106 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,756.23 101
Education $154.80 5

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MONA LISA ALATTAR

NPI 1558624239 · CMS profile ID 1119534

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558624239?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MONA LISA ALATTAR, NPI 1558624239, CMS profile ID 1119534. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558624239?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MONA LISA ALATTAR, NPI 1558624239, CMS profile ID 1119534. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558624239?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MONA LISA ALATTAR, NPI 1558624239, CMS profile ID 1119534, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1558624239?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

106 matching records · $1,911.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 106 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–106 of 106.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $15.6101/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672974959 CMS
Amgen Inc. $16.5701/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662799625 CMS
Novartis Pharmaceuticals Corporation $17.5601/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659071761 CMS
TerSera Therapeutics LLC $25.7201/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699764011 CMS
TerSera Therapeutics LLC $25.7201/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699764009 CMS
Gilead Sciences, Inc. $18.8701/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681469989 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,911.03 106
PY2020 $1,464.97 84
PY2021 $2,054.38 103
PY2022 $6,120.44 131
PY2023 $2,238.80 100
PY2024 $2,520.92 122
PY2025 $2,560.07 107

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $754,365.48 5
PY2024 Principal investigator $199,605.26 7
PY2023 Principal investigator $393.75 2
PY2022 Principal investigator $1,747.75 2
PY2021 Principal investigator $879.25 3
PY2020 Principal investigator $147,241.79 33
PY2019 Principal investigator $29,751.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

5 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $32,400.00 11/12/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A Phase?3b Openlabel Multinational Study Assessing the Efficacy and Safety of DatoDXd Treatment in Patients With HRpositive HER2IHC 0 Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy TROPIONBreast06 No dispute reported 06/30/2026 1185541030
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,733.63 05/22/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190313123
Principal investigator 1 AstraZeneca Pharmaceuticals LP $61,308.99 01/29/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease No dispute reported 06/30/2026 1185541032
Principal investigator 1 AstraZeneca Pharmaceuticals LP $53,375.12 01/03/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185541026
Principal investigator 1 AstraZeneca Pharmaceuticals LP $601,547.74 01/03/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185541028